What oncology imaging capabilities does Perceptive Discovery provide?

Perceptive offers a broad portfolio of in vivo oncology imaging modalities, which include: PET, SPECT, MRI, CT, bioluminescence (BLI), fluorescence (FLI), and cryofluorescence tomography (CFT). These are used to track tumor growth, evaluate biodistribution, measure target engagement, and assess therapeutic efficacy in preclinical models.

What tumor models are available for preclinical oncology studies?

We support a range of tumor model systems, including syngeneic, cell derived xenograft (CDX), and orthotopic tumor models, enabling disease‑relevant oncology research and enhancing translational value for clinical applications.

How does Perceptive support radiopharmaceutical therapy (RPT) and theranostic development in oncology?

Our team provides radiochemistry, imaging, biodistribution, and dosimetry support for radiopharmaceutical therapy programs. We work with a wide variety of therapeutic isotopes, including alpha and beta emitters, and can support theranostic pairs to accelerate translational oncology research.

What therapeutic platforms can be evaluated using Perceptive’s preclinical oncology services?

We have extensive experience supporting radiopharmaceutical therapies, antibody drug conjugates (ADCs), CAR‑T cell therapies, oncolytic viruses, and small molecule therapeutics in oncology imaging studies, ensuring robust data packages across modalities.

How does Perceptive ensure preclinical oncology studies translate into clinical success?

By combining multi‑modality imaging, harmonized workflows, advanced quantitative analysis, and disease‑relevant tumor models, Perceptive generates pharma‑ready data that de‑risk discovery programs and strengthen IND‑enabling oncology packages.

eCOA

Contact us

Home

eCOA

eCOA

Perceptive eClinical and Kayentis partner to tackle increasing digital system complexity in global clinical trials

Top-tier expertise in electronic Clinical Outcome Assessment (eCOA) and Interactive Response Technology (IRT), combined in seamless integrated solution, will enable sponsors
and CROs to streamline clinical trial workflows, reduce digital system fragmentation and lighten site workload

Deeper interoperability enhances clinical data integrity, without compromising highly innovative functions each platform delivers within the fully integrated eCOA-IRT solution

Learn More About Our New eCOA Offering

Stay Updated

Never miss a beat.

eCOA

Perceptive eClinical and Kayentis partner to tackle increasing digital system complexity in global clinical trials

Top-tier expertise in electronic Clinical Outcome Assessment (eCOA) and Interactive Response Technology (IRT), combined in seamless integrated solution, will enable sponsors and CROs to streamline clinical trial workflows, reduce digital system fragmentation and lighten site workload

Deeper interoperability enhances clinical data integrity, without compromising highly innovative functions each platform delivers within the fully integrated eCOA-IRT solution

Learn More About Our New eCOA Offering

Stay Updated

Never miss a beat.

Top-tier expertise in electronic Clinical Outcome Assessment (eCOA) and Interactive Response Technology (IRT), combined in seamless integrated solution, will enable sponsors
and CROs to streamline clinical trial workflows, reduce digital system fragmentation and lighten site workload